Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurogene (NGNE) Asset Writedowns and Impairment (2023 - 2024)

Historic Asset Writedowns and Impairment for Neurogene (NGNE) over the last 2 years, with Q1 2024 value amounting to $91000.0.

  • Neurogene's Asset Writedowns and Impairment changed N/A to $91000.0 in Q1 2024 from the same period last year, while for Dec 2024 it was $91000.0, marking a year-over-year decrease of 900.0%. This contributed to the annual value of $91000.0 for FY2024, which is N/A changed from last year.
  • Latest data reveals that Neurogene reported Asset Writedowns and Impairment of $91000.0 as of Q1 2024.
  • In the past 5 years, Neurogene's Asset Writedowns and Impairment ranged from a high of $100000.0 in Q3 2023 and a low of $91000.0 during Q1 2024